Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
Maria De Santis, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Results demonstrate that this addition provides a statistically significant improvement in disease-free survival with durvalumab plus BCG and durable benefit over long-term follow-up establishing durvalumab plus BCG as a potential new standard for high-risk non-muscle invasive bladder cancer.
These results were presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
Source:
De Santis M, Palou J, Nishiyama H, et al. Durvalumab (D) in combination with Bacillus Calmette-Guerin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Final analysis of the phase III, open-label, randomised POTOMAC trial. Presented at the 2025 ESMO Congress. October 17-21, 2025; Berlin, Germany. LBA108
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
